Isabela

Brazilian Hematologist (Rio de Janeiro).Bone Marrow Transplant Specialist by CEMO/INCA. ESO's Certificate of Competence in Lymphoma CCL6 #lymsm

[Isabela @isaisabelagap]

𝐂𝐞𝐫𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐞 𝐨𝐟 𝐂𝐨𝐦𝐩𝐞𝐭𝐞𝐧𝐜𝐞 𝐢𝐧 𝐋𝐲𝐦𝐩𝐡𝐨𝐦𝐚 and #LyFEcourse Congrats to organizers, thank you F. Cavalli, E. Zucca,@frbertoni @AnastasiosStat2 @PWMJohnson @ESOncology

[Isabela @isaisabelagap]

https://t.co/60TkYQelrV

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS #lymphoma #lymsm https://t.co/LlKzOUJyfu

[Women in Lymphoma - [email protected] @WomenInLymphoma]

Llega la primera serie en español de #WiLingWednesdays
Desde @WomenInLymphoma presentamos la Serie 18 de webinars, con un enfoque especial en Latinoamérica 🌎 y la participación de referentes internacionales de habla hispana
📅 Mayo – Junio 2026
No te lo pierdas!

[Datos Aeronáuticos ◽ @CapLaloVargas]

Cuando piensen que ya están muy viejos para algo...

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology Older patients with LBCL #lymphoma show comparable outcomes to younger patients and product-specific profiles in #CARTcell therapy #lymsm https://t.co/rKRcghQYpu

[ABHH @abhhoficial]

A #BLC2026 segue com debates de alto nível em linfomas: Manto (novas terapias), casos complexos (Richter/intravascular), Linfoma Folicular (decisão individualizada) e LCTP R/R com novos alvos.

A programação vai até 11/04. Ainda dá tempo de participar: https://t.co/KVxImudRLK

[GELTAMO @geltamo]

Continuamos #LinfoMAS2026 con las ponencias de Izaskun Zeberio sobre perfiles de pacientes para estrategias alternativas y Blanca Ferrer sobre biomarcadores predictores de respuesta! 🧪 Avances clave para personalizar tratamientos en linfomas. @geltamo #Linfomas #CART

[Ajay Major, MD, MBA @majorajay]

Vaccination pre/post CAR-T: lymphoma (but not myeloma) pts with preserved pre-CAR seroprotection. Vaccination post CAR significantly increases vaccine responses for both CD19 & BCMA CAR. #ASH25 #tcellrx #lymsm #mmsm

[Isabela @isaisabelagap]

https://t.co/nfanmLQf3E #lymsm

[Isabela @isaisabelagap]

Bridging radiotherapy has become a critical component in the management of patients with relapsed or refractory hematologic ma- lignancies undergoing CAR-T cell therapy

[Women in Lymphoma - [email protected] @WomenInLymphoma]

Women in Lymphoma 2025, in the voices of our Chairs @AnnaSureda5 and Florence Broussais: driving meaningful change through advocacy, collaboration, education and mentorship. https://t.co/cRIVmLoRsF

[Eric Topol @EricTopol]

The one validated intervention to slow aging and extend healthspan is not for sale.
It's exercise.
https://t.co/3ezUq8QvKe

[Eric Topol @EricTopol]

How exercise decreases the risk of cancer and cancer- related mortality by reducing immunosenescence and inflammaging
https://t.co/q4Zm1ovPcb

[Raul Cordoba, MD, PhD @DrRaulCordoba]

FRAIL scale in CLL #frail #frailty #geriheme #geriatrics #geriheme

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology Acalabrutinib to assail #CLL in the #frail #geriheme https://t.co/xwLoenKxS6

[GEHEG @hematogeriatria]

📣 ¿Tienes un caso clínico que te haya hecho replantear cómo cuidar a un paciente mayor con enfermedad hematológica?
Este es el espacio para compartirlo.
#Hematogeriatría #CasosClínicos #MedTwitter @sehh_es @semeg_es

[Graham Collins @graham74GC]

Chapuy et al - R-Pola-Glo in unfit / frail 1L DLBCL
- PhII, 80 pts, not eligible full dose R-CHOP
- by sGA, 91% 'unfit / frail', med age 80y
- ICANS 4%, NRM 4% - 22% G3/4 infectn
- 1y PFS 85% (15mo FU)
- CMR 81% cycle 12
Very impressive and looks well tolerated.
#ASH2025 #lymsm

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

#ASHKudos to @UrviShahMD for getting this to finish line in time for #ASH25!

High fiber plant-based diets in myeloma precursors:

Something our patients ask about, and something we have data for now!

QOL, inflam benefits - and in some cases, alteration of #MMsm trajectory!

[Isabela @isaisabelagap]

Dose-Attenuated-Polatuzumab Vedotine plus CHP vs. Dose-Attenuated -R-CHOP in Patients Aged ≥ 80 Years with Diffuse Large B-Cell Lymphoma: A Retrospective, Propensity Score-Matched Analysis Stratified by Simplified Frailty Score - PMC #lymsm https://t.co/Uknbmqay4G

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Grateful to @BloodJournal, co-authors, and @SWOG for making this #downwithdex piece possible!

Dex 40mg weekly in #MMsm induction:

1️⃣ Not practical even for trial-enrolled patients
2️⃣ Does not improve PFS vs ⬇️ dex

Twitter 🧵 once I’m back from #IMS24!

https://t.co/1Sy1WQpHjk